Amgen needs to get lucky with Repatha

  • Amgen to boost its well diversified portfolio with upcoming FDA decisions.
  • The company is looking to push Repatha to become its star performer.
  • The company stock, at 52 weeks high, looks overheated at the moment.

In an earlier article on Amgen (AMGN), titled Amgen: A Dividend Powerhouse Despite A Maturing Portfolio, I discussed how AMGN’s excellent dividend run makes it interesting despite a 19% run up this year so far (at that point in July). The stock has now moved up to 30%, and it may be time to rethink AMGN.

The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.

An abridged version is available below to our investor members. Login or Subscribe here.